Allos Therapeutics Inc. Earnings Cheat Sheet: Loss Narrows and Beats Estimates

Allos Therapeutics, Inc.’s (NASDAQ:ALTH) third quarter loss narrowed, beating estimates. Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer.

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.

Allos Therapeutics Earnings Cheat Sheet for the Third Quarter

Results: Loss narrowed to $11.2 million (loss of 11 cents per diluted share) from $18.8 million (loss of 18 cents per share) in the same quarter a year earlier.

Revenue: Rose 60.6% to $13.2 million from the year earlier quarter.

Actual vs. Wall St. Expectations: ALTH beat the mean analyst estimate of a loss of 15 cents per share. It beat the average revenue estimate of $12.7 million.

Quoting Management: “We believe our achievement of significant year-over-year revenue growth reflects increased disease-state awareness and brand awareness of FOLOTYN for patients with relapsed or refractory peripheral T-cell lymphoma, for whom there remains an unmet need,” commented Paul L. Berns, president and chief executive officer of Allos Therapeutics.”We ended the third quarter with a strong balance sheet and remain focused on growing U.S. sales of FOLOTYN for relapsed or refractory PTCL while prudently managing our operating expenses. Also, in collaboration with Mundipharma, we are pursuing regulatory approval in the EU, which may occur in early 2012, as well as future label expansion opportunities in T-cell lymphoma.”

Key Stats:

The company has now topped analyst estimates for the last four quarters. It beat the mark by 16 cents in the second quarter, by one cent in the first quarter, and by one cent in the fourth quarter of the last fiscal year.

Looking Forward: Analysts seem more negative about the company’s results for the next quarter than two months ago. The average estimate for the fourth quarter has moved from a loss of 14 cents a share to a loss of 16 cents over the last sixty days. The average estimate for the fiscal year is now 47 cents per share, a rise from the 56 cents predicted ninety days ago.

Competitors to Watch: Seattle Genetics, Inc. (NASDAQ:SGEN), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Hospira, Inc. (NYSE:HSP), Mylan Inc. (NASDAQ:MYL), Cell Therapeutics, Inc. (NASDAQ:CTIC), Cephalon, Inc. (NASDAQ:CEPH), Accentia Biopharmaceuticals, Inc (ABPI), Celgene Corporation (NASDAQ:CELG), Biogen Idec Inc. (NASDAQ:BIIB), and Genta Incorporated (GNTA).

Investing Insights: Here’s Why Chipotle’s Stock Keeps Winning.

(Source: Xignite Financials)